Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-24-000200

Director sold 30,000 shares at $29.03 ($870,900)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Krognes Steve E. · Director

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-09-30 Sale : show line 1 in the form 10b5-1 −30,000 $29.03 $870,900 29,096 D
Open-market sales · 30,000 sh · avg $29.03 · $870,900
Loading xslF345X05/wk-form4_1727901447.xml…